Listen to our latest Investing Matters Podcast episode 'Uncovering opportunities with investment trusts' with The AIC's Richard Stone here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksEVG.L Share News (EVG)

  • There is currently no data for EVG

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Broking boss makes £2.6m profit

Mon, 02nd Nov 2009 16:30

Evolution chief executive Alex Snow has sold £5.2m of shares after being awarded 4.59m shares from two company option schemes after the vesting conditions for the shares were met. The Evolution Group Plc 2000 Executive Share Option Scheme issued 3.09m shares to Snow, Of these, 2.026m did not have any performance criteria, while the award of the rest was based on share price performance. These shares were acquired at 58.67p a share. The total cost was £1.81m. The other 1.5m shares were issued under the Evolution Group Plc 2001 Executive Share Option Scheme - following the achievement of share price performance criteria - and they cost 52.3p each. The total cost was £785,000. That means that Snow made a £2.6m profit on the share sales, which were at 163p a share. The share price is the highest it has been for more than three years. He retains 1.4m of the shares that he was awarded. This still leaves Snow with a higher percentage of the company. He owns 5.6m shares, which is equivalent to 2.42% of Evolution. Snow has taken up all the shares he had under option at the time of the 2008 annual report. Last week, the broker announced that its 2009 profits would be better than expected. Corporate activity has increased in the second half of the year. Funds under management have grown to £5bn at the end of September 2009. In April, Snow raised nearly £927,000 by selling shares at 114p each. That followed the exercise of options over 2m shares at 1p each - a total cost of £20,000. Snow said that the sale proceeds paid for the options and associated tax costs. That means that Snow has made more than £3.5m profit from share sales this year, while retaining 2.57m shares he has been awarded. Top Director BuysAccess Intelligence (ACC) Director name: Mr David LoweAmount purchased: 961,111 @ 4.70p Value: £45,172CLS Holdings (CLI) Director name: Mr Sten A MortstedtAmount purchased: 7,940 @ 443.00p Value: £35,174Jetion Solar Holdings (JHL) Director name: Mr Raymond WongAmount purchased: 30,000 @ 64.50p Value: £19,350Top Director SellsEvolution Group (EVG) Director name: Mr Alex SnowAmount sold: 3,191,565 @ 163.00p Value: £5,202,251Diageo (DGE) Director name: Mr Paul S WalshAmount sold: 99,000 @ 1,000.00p Value: £990,000
More News
24 Jun 2016 09:49

WINNERS & LOSERS SUMMARY: Gold, Dollar Exposure Rewarded Post-Brexit

Read more
31 May 2016 09:59

Evgen Pharma Pleased With "Significant Progress" Since AIM Listing

Read more
3 May 2016 07:42

Evgen Pharma Doses First Patients In Phase 2 SFX-01 Trial For Stroke

Read more
2 Mar 2016 09:44

Evgen Pharma Gets Approvals To Begin Phase II SFX-01 Trial

Read more
19 Jan 2016 15:32

CORRECT: DIRECTOR DEALINGS: Evgen Pharma Directors Buy 136,000 Shares

Read more
19 Jan 2016 14:59

Berkeley Group non-exec picks up first shares

(ShareCast News) - First Derivatives non-executive director David Anderson offloaded 5,000 shares in the software and consulting firm at 1,541p each. The sale brought his interest in the company down to 120,000 shares, or 0.5% of the issued share capital. Elsewhere, Berkeley Group non-executive dir

Read more
19 Jan 2016 09:51

DIRECTOR DEALINGS: Evgen Pharma Directors Bought 136,000 Shares

Read more
4 Jan 2016 11:52

Evgen appoints new Chief Medical Officer

(ShareCast News) - Evgen Pharma announced the appointment of a new Chief Medical Officer on Monday. The AIM-listed clinical stage drug development company, focused on the treatment of cancer and neurological conditions, said Dr Hamina Patel would be appointed to the post. Dr Patel was described by

Read more
7 Dec 2015 09:20

Evgen Says "Very Encouraged" By SFX-01 Development In Maiden Results

Read more
26 Nov 2015 09:45

BROKER RATINGS SUMMARY: OneSavings Upped To Buy, Aldermore Cut To Hold

Read more
23 Nov 2015 09:04

Evgen Pharma Buys Licensing Rights For Range Of Compounds In Spain

Read more
21 Oct 2015 11:24

Evgen Pharma Joins AIM With GBP7.0 Million Raised In IPO (ALLIPO)

Read more
9 Sep 2011 16:55

London close: Stocks dive on euro worries

The volatility continued heading into the weekend and stocks were nursing hefty losses at the close of play. The resignation of European Central Bank official Juergen Stark brought the Eurozone crisis into focus. Stark, a German, like many of his compatriots is unhappy about the Bank's policy of b

Read more
9 Sep 2011 12:33

Broker tips: Home Retail, Premier Farnell, Evolution

Singer Capital Markets has slashed its target price for FTSE 250 retailer Home Retail Group by 29%, after the group's first half results showed continued tough trading at Argos and a challenging second quarter for Homebase. "Whilst not as bad as feared the continued weakness of trade at Argos and o

Read more
9 Sep 2011 12:11

Broker snap: Peel Hunt ups target for Evolution after Investec offer

Following Investec's recommended offer for Evolution, Peel Hunt has raised its target price on the investment banking and stockbroking firm from 86p to 100p to reflect the offer price. Investec, the FTSE 100 South African banking titan, announced on Friday morning that it has made a recommended off

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.